Loading clinical trials...
Loading clinical trials...
Randomized Phase II Study of Human C-raf Kinase Antisense Oligonucleotide Isis 5132 (CGP 69846A) or Human Pkc-Alpha Antisence Oligonucleotide ISIS 3521 (CGP 64128A) in Women With Previously Treated Matastatic Breast Cancer
Conditions
Interventions
ISIS 3521
ISIS 5132
Locations
6
United States
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
Veterans Affairs Medical Center - Chicago (Lakeside)
Chicago, Illinois, United States
Indiana University Cancer Center
Indianapolis, Indiana, United States
Johns Hopkins Oncology Center
Baltimore, Maryland, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, United States
Start Date
July 13, 1998
Primary Completion Date
June 1, 2002
Last Updated
June 18, 2023
NCT07547774
NCT07040891
NCT06257264
NCT07347600
NCT04740697
NCT05491226
Lead Sponsor
Eastern Cooperative Oncology Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions